Interest of β-blockers in patients with right ventricular systemic dysfunction
Authors:
- 2 June 2010
- journal article
- research article
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 20 (6) , 615-619
Abstract
Background: β-blockers improve the prognosis of patients with cardiac failure due to left ventricular systolic dysfunction. The aim of this study was to assess the efficacy of β-blockers in patients with dysfunctional systemic right ventricle. Methods: Fourteen patients with systemic right ventricle following a Mustard or a Senning operation for the transposition of the great arteries, or congenitally corrected transposition were included in the study. All had a decreased systemic right ventricular ejection fraction despite having standard cardiac failure therapy. Quality of life, New York Heart Association class, aerobic capacity, and systemic right ventricular function were assessed before treatment with β-blockers and at the end of the follow-up period, mean of 12.8 months with a range from 3 to 36 months. Results: Change in New York Heart Association class was significant (p = 0.016). Quality of life improved significantly throughout the study from a median grade 2 with a range from 1 to 3 to a median grade 1 with a range from 1 to 2 (p = 0.008). Systemic right ventricular ejection fraction assessed by radionuclide ventriculography improved significantly from a median of 41% (range: 29–53%) to 49% (range: 29–62%; p = 0.031). However, the change in thee ejection fraction assessed by magnetic resonance imaging was not significant from a median of 29% (range: 12–47%) to 32% (range: 22–63%; p = 0.063). Conclusion: In patients with cardiac failure due to systemic right ventricular dysfunction, β-blockers improve New York Heart Association class, quality of life, and systemic right ventricular ejection fraction assessed by radionuclide ventriculography.Keywords
This publication has 20 references indexed in Scilit:
- Relation of Physical Activity, Cardiac Function, Exercise Capacity, and Quality of Life in Patients With a Systemic Right VentricleThe American Journal of Cardiology, 2008
- Effect of Beta Blockers (Carvedilol or Metoprolol XL) in Patients With Transposition of Great Arteries and Dysfunction of the Systemic Right VentricleThe American Journal of Cardiology, 2007
- Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysisEuropean Heart Journal, 2007
- A pilot study on the effects of carvedilol on right ventricular remodelling and exercise tolerance in patients with systemic right ventricleInternational Journal of Cardiology, 2007
- Comparison of segmental and global systemic ventricular function at rest and during dobutamine stress between patients with transposition and congenitally corrected transpositionCardiology in the Young, 2005
- Right ventricular function and ventricular perfusion defects in adults with congenitally corrected transposition: correlation of echocardiography and nuclear medicineCardiology in the Young, 2004
- Regional and global right ventricular dysfunction in asymptomatic or minimally symptomatic patients with congenitally corrected transpositionCardiology in the Young, 2004
- Relation between heart rate, heart rhythm, and reverse left ventricular remodelling in response to carvedilol in patients with chronic heart failure: a single centre, observational studyHeart, 2003
- The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trialThe Lancet, 1999
- The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart FailureNew England Journal of Medicine, 1996